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Real-World Outcomes of Sipuleucel-T Treatment in PROCEED,  
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Neal D. Shore, MD11; Jeffrey Vacirca, MD12; Raoul S. Concepcion, MD13; Ronald F. Tutrone, MD14; Luke T. Nordquist, MD15; 
David I. Quinn, MBBS, PhD16; Vahan Kassabian, MD17; Mark C. Scholz, MD18; Matt Harmon, JD19; Robert C. Tyler, PhD20; 
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BACKGROUND: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) 
(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant  
prostate cancer (mCRPC). METHODS: PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. 
Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interven-
tions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal. RESULTS: In 2011-2017, 1976 patients were followed for 
46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% 
were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 
30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS 
in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median 
time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T–related SAEs 
was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 
11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results–Medicare database was 2.8%; the rate per 100 
person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were  
received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free in-
tervals, respectively. CONCLUSIONS: PROCEED provides contemporary survival data for sipuleucel-T–treated men in a real-world 
setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials 
with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings. Cancer 2019;125: 
4172-4180. © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open 
access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and 
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 
KEYWORDS: immunotherapy, overall survival, prostate cancer, safety.
INTRODUCTION
Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic 
castration-resistant prostate cancer (mCRPC). In the pivotal phase 3 trial Immunotherapy for Prostate Adenocarcinoma 
Treatment (IMPACT; NCT00065442), sipuleucel-T significantly reduced the risk of death among patients with 
mCRPC and improved median overall survival (OS) by 4.1 months versus a placebo.1 Sipuleucel-T is recommended 
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across multiple guidelines2-7 and as a first-line mCRPC 
treatment option2,3,7 (category 1 recommendation by the 
National Comprehensive Cancer Network). In patients 
with low baseline prostate-specific antigen (PSA) lev-
els (≤22.1  ng/mL) in IMPACT, retrospective analyses 
demonstrated a 13-month greater improvement in OS 
with sipuleucel-T versus a placebo.8
Sipuleucel-T was generally well tolerated across sev-
eral prostate cancer (PC) trials.1,9-14 The most common 
adverse events (≥15%) were chills, fatigue, fever, back pain, 
nausea, joint ache, and headache of mostly mild to mod-
erate severity. Incidences of grade 3 and 4 adverse events 
were 23.6% and 4.0%, respectively, with sipuleucel-T and 
25.1% and 3.3%, respectively, with a placebo. Serious ad-
verse events (SAEs) included acute infusion reactions and 
cerebrovascular events (CVEs).14 Data from 4 randomized, 
double-blind, placebo-controlled clinical trials (D9901 
[NCT00005947],12,13 D9902A [NCT01133704],13 
IMPACT,1 and PROTECT [NCT00779402]9) showed 
that CVEs, excluding transient ischemic attacks (TIAs), 
occurred in 3.5% (sipuleucel-T) and 2.6% (placebo) of 
patients (not statistically significant).14 The clinical signif-
icance and causal relationship are uncertain.
The PROVENGE Registry for the Observation, 
Collection, and Evaluation of Experience Data 
(PROCEED; NCT0136890), evaluated real-world safety 
data and provided an opportunity to analyze efficacy 
outcomes of mCRPC management involving sipuleu-
cel-T during a time of rapidly evolving management 
protocols.
MATERIALS AND METHODS
Study Design and Patients
PROCEED was a multicenter, open-label, observational 
registry conducted at urology and medical oncology 
clinics in private practice and at academic sites (see the 
Supporting Methods section in the supporting informa-
tion). The primary and secondary objectives were to quan-
tify CVE risk and OS, respectively. SAEs were collected. 
For a protocol-specified, exploratory objective, the propor-
tion of patients receiving subsequent anticancer interven-
tions (ACIs) was assessed. Both the protocol and its single 
amendment were approved by each center’s Institutional 
Review Board before patient enrollment. Before participa-
tion, patients provided written informed consent.
Treatment
No randomization, blinding, or treatment masking 
was conducted. Patients underwent a 1.5 to 2.0× blood 
volume leukapheresis for antigen-presenting cell (APC) 
isolation with a sipuleucel-T infusion 3 to 4 days later; 
this was repeated at approximately 2-week intervals for 
3 infusions.
Study Procedures
Safety and survival were assessed during normal clinical 
practice and were reported every 3 months after the final 
sipuleucel-T infusion. Use of central venous catheters at 
the physician’s discretion was recorded. PROCEED did 
not require the recording of all PC-related events after 
sipuleucel-T treatment. ACI use after the first infusion of 
sipuleucel-T was recorded. Decisions to use further treat-
ment and the choice and timing of ACI use were at the 
physician’s discretion.
All SAEs (according to MedDRA version 19.1) from 
the first sipuleucel-T infusion through 60 days after the 
final infusion were captured. Thereafter, SAEs at least pos-
sibly related to sipuleucel-T were recorded. All CVE data 
were collected, regardless of causality, severity, or outcome, 
throughout PROCEED. CVEs, adjudicated by an inde-
pendent neurologist, included all strokes (ischemic and 
hemorrhagic), intracranial hemorrhage, and TIAs (focal 
neurologic deficit episodes resolving within 24 hours).15
Patients were followed for ≥3 years or until death 
or study withdrawal. The cause of death was reported 
on a case report form. An end-of-study closeout form 
was completed to ascertain death. For patients lost to 
follow-up, sites performed a death-sweep search for 
obituaries.
Statistical Analyses
The sample size was based on an evaluation of the CVE 
rate. With ≥1500 patients followed for ≥3 years (4500 
person-years), the 95% confidence interval (CI) for es-
timating the CVE incidence rate per 100 patient-years 
would have a width of <1 unit as long as the observed 
rate was <2.8/100 patient-years.16 For 1500 patients, the 
probability of observing 1 or more occurrences of a rare 
event (1 in 1000) would be 0.78. The sample size was 
increased from 1500 to allow for 4500 person-years of 
follow-up.
The predefined analysis population was all patients 
receiving 1 or more full or partial (>0 mL) sipuleucel-T 
infusions. Endpoints were summarized descriptively un-
less otherwise stated. All analyses were performed with 
SAS (versions 9.2 and 9.4; SAS Institute, Inc, Cary, 
North Carolina).
OS was measured from the date of the first sipu-
leucel-T infusion for ≥3  years or until the patient had 
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otherwise gone off the study. If death was not reported, 
patients were censored from the last study visit. OS data 
were analyzed with Kaplan-Meier methodology; Cox 
proportional hazards regression was used to calculate 
hazard ratios and 95% CIs. These were post hoc analy-
ses with P values that were not adjusted for multiplicity. 
Univariable, stepwise Cox modeling and multivariable 
analysis were performed to assess for independent base-
line predictors of OS that had both clinical and statistical 
relevance. Variables were selected in a stepwise process for 
the final multivariable analysis model at a .1 significance 
level (see the Supporting Methods for more details). The 
association of OS with natural logarithm–transformed 
sipuleucel-T product parameters (APC activation, APC 
cell count, and total nucleated cell count) was estimated 
with a Cox proportional hazards regression model; statis-
tical significance was a 2-tailed P value <.05. A post hoc 
analysis evaluated OS by baseline PSA quartiles; hazard 
ratios and 95% CIs were calculated by the Cox regression 
model.
Primary summarization of CVEs excluded TIAs 
for consistency with how CVE rates had been previously 
defined.14 CVEs including TIAs were summarized sep-
arately. The PROCEED CVE incidence was compared 
with a retrospective analysis of the incidence of first-time 
CVEs in men 65 years old or older with PC, including 
those with metastatic PC and a castrated state, within the 
Surveillance, Epidemiology, and End Results (SEER)–
Medicare database in 1999-2013 (see the supporting 
information).
An exploratory analysis described the proportion of 
patients receiving ACIs after the first sipuleucel-T infu-
sion. The Kaplan-Meier method estimated the propor-
tion of ACI use at 1 and 2 years.
RESULTS
Patients and Treatment
PROCEED was conducted from January 27, 2011 (the 
first patient registered), to January 17, 2017 (the last pa-
tient visit); 1976 consenting patients were enrolled across 
192 sites. Overall, 1902 patients received 1 or more sip-
uleucel-T infusions: 1248 (65.6%) were treated in oncol-
ogy practices, and 654 (34.4%) were treated in urology 
practices. Most patients (79.1%) received sipuleucel-T at 
140 community clinics; the remainder received it at 52 
academic centers (see the Supporting Results in the sup-
porting information for study discontinuation reasons).
Central venous catheters were used in 891 pa-
tients (46.8%). Overall, 1813 patients (95.3%) received 
3 sipuleucel-T infusions, 57 (3.0%) received 2, and 32 
(1.7%) received 1. Reasons for 3 or fewer infusions in-
cluded an SAE (34 [1.8%]), other (32 [1.7%]), disease 
progression after the first infusion (22 [1.2%]), patient 
refusal (16 [0.8%]; including a refusal to transfer loca-
tion or answer study questions), and venous access prob-
lems (4 [0.2%]). Multiple reasons for noninfusion were 
possible.
Table 1 lists patient characteristics for PROCEED 
and for IMPACT sipuleucel-T–treated patients for com-
parison.1 The median patient age was 72 years; 86.7% 
were white, and 11.6% were African American. Most pa-
tients had an Eastern Cooperative Oncology Group per-
formance status of 0 or 1. The median baseline PSA level 
was 15.0  ng/mL (interquartile range, 5.2-46.1  ng/mL). 
Some patients received prior docetaxel, abiraterone, or 
enzalutamide (commercially or as an investigational 
agent). Most had bone-dominant metastases with or 
without lymph node involvement. The metastatic site or 
status was not reported for 19 patients (1.0%). Supporting 
Table 1 lists PROCEED baseline CVE risk factors.
Overall Survival
The median OS was 30.7 months (95% CI, 28.6-32.2 
months; Fig. 1); the median follow-up was 46.6 months. 
During follow-up, 1255 patients (66.0%) died. Death 
or survival could not be ascertained for 45 patients. 
The main cause of death was PC progression (964 of 
1255 [76.8%]); the median time to PC-specific death 
was 42.7  months (95% CI, 39.4-46.2  months). Other 
causes of death were unknown (154 [12.3%]), other (136 
[10.8%]), a cardiac event (42 [3.3%]), a CVE (17 [1.4%]), 
and a new primary cancer (8 [0.6%]). More than 1 cause 
of death could be recorded for a patient.
A post hoc analysis indicated that the median OS 
was longer for patients in the lowest baseline PSA quar-
tile (≤5.27 ng/mL) than patients in the second (>5.27 
to ≤15.08  ng/mL), third (>15.08 to ≤46  ng/mL), and 
fourth quartiles (>46  ng/mL): 47.7  months (95% 
CI, 43.5-50.7  months), 33.2  months (95% CI, 30.9-
35.5 months), 27.2 months (95% CI, 24.1-29.8 months), 
and 18.4  months (95% CI, 15.9-21.2  months), respec-
tively. The hazard ratios for each quartile versus the 
lowest quartile were 1.6 (95% CI, 1.3-1.9), 2.0 (95% CI, 
1.7-2.4), and 3.0 (95% CI, 2.6-3.6), respectively.
Univariable analyses showed that 15 evaluated 
baseline characteristics were significant predictors of 
OS (Supporting Table 2). Eleven characteristics were 
included in the final primary multivariable analysis. Of 
these, 10 were associated with OS at a significance level 
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TABLE 1. Demographics, Baseline Disease Characteristics, and Prior Prostate Cancer Treatments in 
PROCEED and IMPACT1
Parameter
PROCEED Safety Population 
(n = 1902)
IMPACT Sipuleucel-T–Treated Arm 
(n = 341)
Age, median (range, min-max), y 72 (42-97) 72 (49-91)
Race, No. (%)
White 1649 (86.7) 305 (89.4)
Black or African American 221 (11.6) 23 (6.7)
Asian 22 (1.2) 2 (0.6)
Other 10 (0.5) 11 (3.2)
ECOG performance status, No. (%)
0 1265 (66.5) 280 (82.1)
1 571 (30.0) 61 (17.9)
≥2 42 (2.2) 0
Unknown 24 (1.3) 0
Gleason sum reported, No. (%)
≤7 790 (41.5) 257 (75.4)
≥8 963 (50.6) 84 (24.6)
Unknown 149 (7.8) 0
Charlson Comorbidity Index, No. (%) NA
Low (0-1) 1682 (88.4)
High (≥2) 220 (11.6)
Bone metastases, No. (%) n = 1595
1-10 1117 (70.0) 195 (57.2)
>10 274 (17.2) 146 (42.8)
Unknown 204 (12.8) 0
Disease locations, No. (%) n = 1883 n = 340
Bone only 1223 (64.3) 173 (50.7)
Bone and lymph nodes 313 (16.5) 143 (41.9)
Lymph nodes only 257 (13.5) 24 (7.0)
Visceral ± bone or lymph nodes 90 (4.7) 0
Liver 21 (1.1) 0
Lung 61 (3.2) 0
Brain 2 (0.1) 0
Visceral site(s) not reported 13 (0.7) 0
Laboratory parameters, median (IQR, Q1-Q3)
ALP, U/L 82 (63-115) 99 (75-146)
n = 1499
Hemoglobin, g/dL 12.8 (11.8-13.7) 12.9 (11.7-13.7)
n = 1794
Lactate dehydrogenase, U/L 186 (159-218) 194 (172-224)
n = 644 n = 340
PSA, ng/mL 15.0 (5.2-46.1) 51.7 (22.5-140.3)
n = 1884
Interval from diagnosis to first sipuleucel-T  
infusion, median (IQR, Q1-Q3), y
5.0 (2.3-9.4) 7.1 (4.4-10.7)
n = 1599
Prior local cancer therapy, No. (%)
No local therapy (systemic therapy only) 429 (22.6) 85 (24.9)
Radical prostatectomy alone 310 (16.3) 46 (13.5)
Radical prostatectomy + radiation 379 (19.9) 73 (21.4)
Radiation therapy alone (external beam/
brachytherapy)
564 (29.7) 112 (32.8)
Prior systemic cancer therapy, No. (%)
Androgen-targeting therapya 1881 (98.1) 279 (81.8)b 
LHRH antagonist 382 (20.1) —
LHRH agonist 1566 (82.3) 341 (100)c 
Abiraterone 157 (8.3) 0
Enzalutamide 54 (2.8) 0
Chemotherapy
Docetaxel 215 (11.3) 53 (15.5)
Cabazitaxel 32 (1.7) 0
Radium 223 1 (0.1) 0
Abbreviations: ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; IMPACT, Immunotherapy for Prostate Adenocarcinoma Treatment; 
IQR, interquartile range; LHRH, luteinizing hormone releasing hormone; max, maximum; min, minimum; NA, not applicable; PROCEED, PROVENGE Registry 
for the Observation, Collection, and Evaluation of Experience Data; PSA, prostate-specific antigen; Q1, first quartile; Q3, third quartile.
PROCEED was observational, so calculations were based on values from the number of patients for whom data were available.
aExcluded enzalutamide.
bPatients received complete androgen blockade treatment.
cPatients received an LHRH analogue.
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below .05 (Table 2): age, ethnicity, Eastern Cooperative 
Oncology Group performance status, time since diagno-
sis, PSA, alkaline phosphatase, hemoglobin, lymph node 
only metastases, prior abiraterone/enzalutamide, and 
prior docetaxel/cabazitaxel.
Cumulative sipuleucel-T product parameters (Sup-
porting Table 3) per unit increase correlated with OS.
Safety
All-grade SAEs, regardless of causality, were reported 
in 260 patients (13.7%); the most common SAEs were 
disease progression (28 patients), cerebrovascular acci-
dent (16 patients), chills (13 patients), syncope (12 pa-
tients), and device-related infection (10 patients; Table 3). 
Seventy-four patients (3.9%) had 1 or more SAEs con-
sidered possibly or probably related to the study drug (all 
grades); the most common were chills (13 [0.7%]), cer-
ebrovascular accident (9 [0.5%]), deep vein thrombosis 
(4 [0.2%]), device-related infection (4 [0.2%]), pulmonary 
embolism (4 [0.2%]), and pyrexia (4 [0.2%]). Grade 3 to 
5 SAEs, regardless of causality, occurred in 175 patients 
(9.2%; Table 3). The incidence of grade 4 SAEs was 1.1% 
(n =  21). Fifty-two patients (2.7%) had grade 5 SAEs, 
and 22 deaths were due to disease progression. Central 
venous catheter–related SAEs were reported in 19 patients 
(1.0%); 13 were grade 3 or 4 with no grade 5 SAEs. Of 
these 19 patients, 2 and 5 had 1 and 2 sipuleucel-T infu-
sions, respectively.
The overall incidence of adjudicated CVEs (ex-
cluding TIAs) in PROCEED was 2.8% (n =  54), and 
the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6; 
Supporting Table 4). In the SEER-Medicare data analy-
ses of men with PC at diagnosis who were metastatic at 
Figure 1. OS in PROCEED as a Kaplan-Meier plot with a 95% Hall-Wellner band. CI indicates confidence interval; OS, overall 
survival; PROCEED, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
TABLE 2. Final Primary Multivariable Analysis of 
Overall Survival in PROCEED
Baseline Covariate HR (95% CI) Pa 
Log PSA (ng/mL) 1.22 (1.16-1.27) <.001
Hemoglobin, per g/dL increase 0.87 (0.83-0.91) <.001
ECOG performance status, >0 vs 0 1.22 (1.05-1.42) .009
Log ALP (U/L) 1.60 (1.42-1.81) <.001
Age (y), >median vs ≤median 1.30 (1.12-1.50) <.001
Race, white vs all others 1.64 (1.30-2.06) <.001
Time since diagnosis (y), >median vs ≤median 0.72 (0.62-0.83) <.001
Lymph node only metastases, yes vs no 0.79 (0.63-0.99) .044
Visceral metastases, any vs none 1.30 (0.95-1.78) .098
Prior docetaxel/cabazitaxel, yes vs no 1.54 (1.25-1.90) <.001
Prior abiraterone/enzalutamide, yes vs no 1.53 (1.16-1.27) <.001
Abbreviations: ALP, alkaline phosphatase; CI, confidence interval; ECOG, 
Eastern Cooperative Oncology Group; HR, hazard ratio; PROCEED, 
PROVENGE Registry for the Observation, Collection, and Evaluation of 
Experience Data; PSA, prostate-specific antigen.
aMultivariable Cox modeling.
Sipuleucel-T Real-World Registry/Higano et al
4177Cancer  December 1, 2019
follow-up and in a castrated state (n = 11,972), the CVE 
incidence (excluding TIAs) was 2.8%, and the rate per 
100 person-years was 1.5 (95% CI, 1.4-1.7; Supporting 
Table 5).
Subgroup analyses of CVEs (excluding TIAs) 
showed higher CVE rates in older patients, African 
Americans, patients with more advanced PC, and those 
with preexisting conditions associated with CVEs 
(Supporting Table 6). Nine patients had a TIA (3 con-
current with another CVE and 6 in isolation). Thus, 60 
PROCEED patients (3.2%) had CVEs, including TIAs, 
and the rate per 100 person-years was 1.3 (95% CI, 1.0-1.7; 
Supporting Table 4). The observed median time to a CVE 
(including TIAs) from the last sipuleucel-T infusion was 
321 days (10.5 months; interquartile range, 79-689 days 
or 2.6-22.6 months). For patients with a CVE (includ-
ing TIAs), the number and percent of patients with 
CVE onset within ≤30, 31-60, 61-180, and >181 days 
of the most recent sipuleucel-T infusion were 10 (16.7%), 
4 (6.7%), 9 (15.0%) and 37 (61.7%), respectively. No 
appreciable differences in the CVE ± TIA incidence or 
rate were observed between patients with or without a 
central venous catheter (Supporting Table 7).
Protocol-Specified, Exploratory Analysis: ACIs
Three hundred thirty-eight patients (17.8%) received an 
OS-prolonging ACI (abiraterone, enzalutamide, doc-
etaxel, cabazitaxel, or radium 223) before sipuleucel-T. 
Approximately one-third of the patients (32.5%) did not 
receive any OS-prolonging ACI at 1  year, and 17.4% 
did not at 2 years after sipuleucel-T treatment. Of these 
patients, 9.5% and 7.4% had received an ACI before 
sipuleucel-T; thus, most of these patients had sipuleucel-T 
as first-line mCRPC therapy. Among patients in the 
lowest baseline PSA quartile (≤5.27 ng/mL), 44.1% and 
25.8% did not receive an ACI at 1 and 2 years, respec-
tively. Of these, 94.3% and 95.0% received sipuleucel-T 
before any other ACI.
During PROCEED, 1483 of all patients (78.0%) 
received 1 or more OS-prolonging ACIs, and 48.3% 
received 2 or more lines of treatment after sipuleucel-T 
(Table 4). The most commonly used OS-prolonging 
ACIs after sipuleucel-T treatment were abiraterone (1036 
[54.5%]), enzalutamide (831 [43.7%]), and docetaxel 
TABLE 3. Overall Summary of All-Grade SAEs and 
Grade 3 to 5 SAEs Occurring in 3 (0.2%)  
or More Patients (in the All-Grade List) Regardless 
of Causality (n = 1902) in PROCEED
SAE
No. (%)
All Grades Grades 3-5
Any SAE 260 (13.7) 175 (9.2)
Disease progression 28 (1.5) 25 (1.3)
Cerebrovascular accident 16 (0.8) 11 (0.6)
Chills 13 (0.7) 0 (0)
Syncope 12 (0.6) 7 (0.4)
Device-related infection 10 (0.5) 7 (0.4)
Acute kidney injury 8 (0.4) 7 (0.4)
Deep vein thrombosis 8 (0.4) 2 (0.1)
Pulmonary embolism 8 (0.4) 7 (0.4)
Anemia 7 (0.4) 2 (0.1)
Dyspnea 7 (0.4) 6 (0.3)
Chest pain 6 (0.3) 2 (0.1)
Myocardial infarction 6 (0.3) 5 (0.3)
Pyrexia 6 (0.3) 2 (0.1)
Subdural hematoma 6 (0.3) 6 (0.3)
TIA 6 (0.3) 1 (0.1)
Cerebral hemorrhage 5 (0.3) 5 (0.3)
Pneumonia 5 (0.3) 3 (0.2)
Cerebral infarction 4 (0.2) 4 (0.2)
Congestive cardiac failure 4 (0.2) 3 (0.2)
Dehydration 4 (0.2) 3 (0.2)
Device-related sepsis 4 (0.2) 3 (0.2)
Intracranial hemorrhage 4 (0.2) 2 (0.1)
Nausea 4 (0.2) 1 (0.1)
Spinal cord compression 4 (0.2) 4 (0.2)
Vomiting 4 (0.2) 4 (0.2)
Asthenia 3 (0.2) 1 (0.1)
Atrial fibrillation 3 (0.2) 1 (0.1)
Back pain 3 (0.2) 2 (0.1)
Bacteremia 3 (0.2) 1 (0.1)
Confusional state 3 (0.2) 1 (0.1)
Constipation 3 (0.2) 2 (0.1)
Fall 3 (0.2) 3 (0.2)
Hematuria 3 (0.2) 1 (0.1)
Hypotension 3 (0.2) 2 (0.2)
Infusion-related reaction 3 (0.2) 2 (0.2)
Presyncope 3 (0.2) 1 (0.1)
Abbreviations: PROCEED, PROVENGE Registry for the Observation, 
Collection, and Evaluation of Experience Data; SAE, serious adverse event; 
TIA, transient ischemic attack.
TABLE 4. Proportion of Patients Receiving an 






Patients Who Died 
During PROCEED 
(n = 1255)
No. of posttreatment ACIs, 
No. (%)
0 419 (22.0) 287 (22.9)
1 565 (29.7) 329 (26.2)
2 462 (24.3) 326 (26.0)
3 319 (16.8) 216 (17.2)
4 126 (6.6) 87 (6.9)
5 11 (0.6) 10 (0.8)
Specific posttreatment ACI, 
No. (%)
Abiraterone 1036 (54.5) 663 (52.8)
Enzalutamide 831 (43.7) 514 (41.0)
Docetaxel 739 (38.9) 553 (44.1)
Cabazitaxel 309 (16.2) 236 (18.8)
Radium 223 90 (4.7) 61 (4.9)
Abbreviation: ACI, anticancer intervention; PROCEED, PROVENGE Registry 
for the Observation, Collection, and Evaluation of Experience Data.
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(739 [38.9%]; Table 4). Having sipuleucel-T as the only 
OS-prolonging treatment in PROCEED was reported in 
22.0% of the patients (n = 419).
Similar patterns of ACI use were observed in pa-
tients who died during PROCEED (n =  1255), with 
968 patients (77.1%) receiving 1 or more OS-prolonging 
ACIs and 50.9% receiving 2 or more lines of treat-
ment after sipuleucel-T (Table 4). The most common 
OS-prolonging ACIs reported in those who died were 
abiraterone (52.8%), docetaxel (44.1%) and enzalut-
amide (41.0%; Table 4). Sipuleucel-T was the only OS-
prolonging ACI prescribed in PROCEED for 22.9% of 
these patients (n = 287).
DISCUSSION
Since the conduct of the phase 3 IMPACT trial1 with 
sipuleucel-T (2003-2007), mCRPC treatments17-22 and 
guidelines2-7 have rapidly evolved. The PROCEED study 
(2011-2017), which includes the largest mCRPC patient 
population treated with sipuleucel-T and prospectively 
followed in a real-world setting, offers interesting obser-
vations about patients with mCRPC, sipuleucel-T use, 
and the use of other ACIs since IMPACT. The baseline 
characteristics of PROCEED patients reveal clinical 
practice changes (Table 1). Although the median age was 
similar, the median baseline PSA level was much lower 
in PROCEED versus IMPACT (15.0 vs 51.7  ng/mL); 
this is noteworthy because a previous analysis of 
IMPACT showed a much greater OS benefit from sip-
uleucel-T versus a placebo in patients with lower baseline 
PSA levels.8 Most PROCEED patients had a good per-
formance status, although in comparison with IMPACT, 
the performance status was somewhat worse (likely be-
cause randomized clinical trials have more stringent eli-
gibility criteria). The Gleason score was also higher in 
PROCEED. PROCEED enrolled a higher proportion 
of African American patients than IMPACT (11.6% 
vs 6.7%), and this is notable because this population is 
often underrepresented in clinical trials. Visceral metas-
tases, an IMPACT exclusion criterion, were reported in 
4.7% of PROCEED patients. Furthermore, PROCEED 
spanned a period of unprecedented progress in mCRPC 
management as 4 life-extending therapies became avail-
able: abiraterone acetate,17,18 enzalutamide,19,20 cabazi-
taxel,21 and radium 223.22 Thus, in PROCEED, the 
median OS (30.7 months) likely, in part, reflects use of 
these life-prolonging drugs with sipuleucel-T in contrast 
to the IMPACT (median OS, 25.8 months1) era, in ad-
dition to the use of sipuleucel-T in patients with lower 
PSA levels.
PROCEED provides further evidence of sipu-
leucel-T safety and tolerability in a real-world setting. 
Particularly in an elderly patient population, the safety 
profile of a treatment deserves careful consideration in 
decision making. Importantly, the SAE incidence in 
PROCEED was low and was comparable to that docu-
mented during IMPACT.1 A previous analysis of pooled 
data from 4 phase 3 trials reported CVE rates (exclud-
ing TIAs) of 3.5% (sipuleucel-T) and 2.6% (placebo).14 
The causal relationship of sipuleucel-T with CVEs is 
unclear. Men with mCRPC are typically elderly with 
multiple comorbidities that increase the risk of cardio-
vascular events and CVEs. In PROCEED, a CVE rate 
of 2.8% was reported. Incidentally, the CVE rate was 
2.8% in a SEER-Medicare database analysis with more 
than 10,000 patients with metastatic PC in a castrated 
state. Furthermore, subgroup analyses by baseline fac-
tors in PROCEED demonstrated that older patients 
and those with baseline CVE factors had higher rates 
of CVEs (Supporting Table 6), and this was consis-
tent with published findings.23-25 Moreover, although 
central venous catheter use (which varied greatly by 
site) for leukapheresis was high in PROCEED, over-
all, this practice did not increase CVE risk (Supporting 
Table 7).
PROCEED also offers confirmation of correlative 
findings noted in prior phase 3 studies. Patients in the 
lowest baseline PSA quartile (PSA ≤ 5.27 ng/mL) had 
significantly longer OS (median survival, 47.7 months) 
than those in higher PSA quartiles. Similar findings 
were seen in the post hoc analysis of IMPACT, which 
demonstrated a greater OS benefit in lower baseline PSA 
quartiles versus higher baseline PSA quartiles and also 
suggested that sipuleucel-T was superior to a placebo in 
each quartile.8 Likewise, similar correlations with im-
mune parameters and OS were seen in both PROCEED 
and IMPACT; in vitro indicators of immune activa-
tion and product potency (cumulative APC activation, 
APC count, and total nucleated cell count in the prod-
uct) were significantly correlated with OS (Supporting 
Table 3).26,27
PROCEED also exhibited 10 baseline charac-
teristics that were independent predictors of OS in 
PROCEED (Table 2). The examined covariates were 
selected on the basis of those previously observed to be 
clinically and statistically relevant in this population. 
Our findings, though broadly consistent with the Halabi 
model,28 also differ in terms of which significant predic-
tors were identified, potentially because of the treatment 
being received (chemotherapy in the population used for 
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the Halabi nomogram and sipuleucel-T for the current 
study), the data coming from a clinical trial versus a reg-
istry, the time periods during which the various studies 
informing these analyses were conducted and the changes 
in available therapies and PSA levels guiding treatment, 
and so on. One notable observation is the emergence of 
race as a statistically significant predictor, and this po-
tentially reflects the relatively high enrollment of African 
Americans in PROCEED (12%). Further research is 
warranted to explore these findings.
Another notable finding in PROCEED is that a 
substantial number of patients experienced a long in-
terval between sipuleucel-T and subsequent therapy 
with abiraterone, enzalutamide, docetaxel, cabazitaxel, 
or radium 223. Approximately one-third and one-sixth 
of the patients had not received any of these agents 
1 and 2 years, respectively, after sipuleucel-T. For most of 
these patients, sipuleucel-T was their first OS-prolonging 
mCRPC therapy; having a long treatment-free interval 
after sipuleucel-T may reflect patient selection as well as 
the clinical benefit of sipuleucel-T. Interestingly, 22% of 
the overall PROCEED population received sipuleucel-T 
as their only OS-prolonging treatment for mCRPC. The 
reasons for this are unclear. However, the long median 
time to death from PC of 42.7  months observed pro-
vides further evidence for the early use of sipuleucel-T 
for mCRPC followed by other ACIs, as recommended by 
the National Comprehensive Cancer Network and other 
guidelines.2-4,7
PROCEED has several limitations. Although OS 
was prospectively determined, there was no comparator 
group, so a survival benefit could not be determined. 
Nonetheless, this observation gives an accurate picture of 
expected OS with sipuleucel-T plus other life-prolonging 
drugs that were not available when IMPACT was con-
ducted. Similar reasoning applies to SAE and CVE risk 
in that there was no placebo arm; hence, the results are 
descriptive.
PROCEED provides a real-world portrait of the 
safety profile of sipuleucel-T and defines the expected 
OS after sipuleucel-T in patients with mCRPC in the 
modern era of 5 additional life-prolonging agents. This 
information may be useful in powering future combina-
tion trials with sipuleucel-T, and studying the sequencing 
of therapies in this large population may shed light on 
optimal treatment approaches.
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